Day: July 6, 2022

Denso’s strength remains its reliance on domestic powertrain and thermal business with Toyota LONDON, July 06, 2022 (GLOBE NEWSWIRE) — The “Automotive Heating, Ventilation and Air-Conditioning (HVAC) Market and Trend Analysis by Technology, Key Companies and Forecast, 2021-2036” report offered by GlobalData Plc, provides a comprehensive overview of the global automotive heating, ventilation, and air-conditioning sector, major suppliers, top 14 markets, technology trends, and market size forecasts. Once a premium feature, HVAC is nearing ubiquity globally, but that is not stopping further development. Also, electrified vehicles are increasing the pressure on HVAC systems to become more efficient. As well as efficiency there’s a big push to improve the cabin air quality provided by HVAC systems. There are now just four major...

SAMPO PLC                 STOCK EXCHANGE RELEASE         06/07/2022 at 08:30 am Sampo plc’s share buybacks 05/07/2022 On 05/07/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  12,699 41.40 AQEU  19,225 41.31 CEUX  5,959 41.31 TQEX  127,117 41.54 XHELTOTAL 165,000 41.49  *rounded to two decimals                 On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based...

Lunsumio® (mosunetuzumab) could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma Application is based on results from the pivotal phase I/II study showing Lunsumio induced high and durable complete response rates in people with follicular lymphoma who received two or more prior therapies Lunsumio is a fixed-duration treatment option with the potential to be administered in an outpatient settingBasel, 6 July 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for Lunsumio® (mosunetuzumab), a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed...

In 2022 Q2, 4.7 million tonnes of cargo and 1.9 million passengers passed through the harbours of Tallinna Sadam. Compared to the same period of previous year, the number of passengers increased by 218% i.e. by 1.3 million passengers whereas the cargo volume decreased by 21%. The number of vessel calls increased by 6% to 1948 calls. The number of passengers travelling between the Estonian mainland and the main islands increased by 8% and the number of vehicles by 1%. The number of charter days of the icebreaker Botnica stayed at the same level as in the previous year, utility rate of the vessel was 26%. According to Valdo Kalm, chairman of the management board of Tallinna Sadam, the beginning of summer and the holiday period have brought many passengers from nearby countries, especially on the Tallinn-Helsinki line, where the number of...

Judith Bischof will succeed Alfred Münch upon his retirement as General Counsel and Head of Group Legal Services from 1 September 2022 As General Counsel she will be a member of the newly created Executive Leadership Team She graduated in law and holds a Master of International Business and Law, an Executive MBA as well as a doctorate After working at court and prestigious international law firms, she has spent the last ten years serving as General Counsel first at Ascom and then at RUAG InternationalMUTTENZ, JULY 6, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today announced the appointment of Judith Bischof as General Counsel as of 1 September 2022. She will succeed Alfred Münch, who is retiring after having served in this position for the last twelve years. As General Counsel Judith Bischof will...

July 6, 2022 Hamilton, Bermuda Flex LNG updates on the market, employment and revenue guidance Flex LNG Ltd. (“Flex LNG” or the “Company”) will be providing an update on employment, adjusted revenue guidance and the general market during a presentation at Arctic Securities today. Given the recently announced Time Charter Agreements for Flex Rainbow, Flex Enterprise and Flex Amber which have secured in total 24 years of fixed hire employment, Flex LNG has made the following positive adjustments to its revenue guidance for the year:Expected revenues in Q2-22: ~$85m vs. $80m Expected revenues in Q3-22: ~$90m vs. $82-92m Expected revenues in Q4-22: $90-100m vs. $85-105mFlex LNG also guide higher revenues and Time Charter Equivalent Earnings (TCE) in 2023 than 2022 due to repricing of its employment portfolio and...

RADA expects revenue of approximately $22.5 million for the second quarter of 2022; In light of the Company’s pending merger with Leonardo DRS, RADA is withdrawing its full year 2022 revenue guidance NETANYA, Israel, July 06, 2022 (GLOBE NEWSWIRE) — RADA Electronic Industries Ltd. (NASDAQ: RADA, TASE: RADA), a leading global provider of advanced software-defined tactical radars for the maneuver force, today provided a financial update for year 2022. Revenues for the second quarter of 2022 are expected to be approximately $22.5 million, at a similar level to that of the first quarter of this year. In light of the pending merger with Leonardo DRS, which is expected to be completed during the upcoming fourth quarter, RADA is withdrawing its full year 2022 guidance. Dov Sella, RADA’s CEO, commented, “It is taking longer for RADA to...

SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) — Inmagene Biopharmaceuticals (“Inmagene“) and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study is a multi-stage, double-blind, randomized, placebo-controlled, dose-escalation study in healthy volunteers, and a dose-escalation and parallel design, multiple-dose study in adult patients with moderate to severe atopic dermatitis. The study will be used to evaluate the safety, tolerability and efficacy of IMG-007 in patients with atopic dermatitis. Additional details will be found at clinicaltrials.gov, using identifier NCT05353972. “Dosing...